Indivior Pharmaceuticals (INDV) Share-based Compensation (2024 - 2026)

Indivior Pharmaceuticals' Share-based Compensation history runs 3 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 200.0% year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $32.0 million, a 540.0% increase from a year earlier, with the FY2025 full-year figure at $26.0 million, up 18.18% from the prior year.
• Share-based Compensation retreated to $9.0 million in Q1 2026 per INDV's latest filing, from $23.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $23.0 million in Q4 2025 and bottomed at -$8.0 million in Q2 2024.
• The 3-year median for Share-based Compensation is $8.0 million (2024), against an average of $8.1 million.
• Biggest YoY gain for Share-based Compensation was 1050.0% in 2025; the steepest drop was 85.0% in 2025.
• Year by year, Share-based Compensation stood at $2.0 million in 2024, then soared by 1050.0% to $23.0 million in 2025, then tumbled by 60.87% to $9.0 million in 2026.
• Per Business Quant, the three latest INDV Share-based Compensation figures stand at $9.0 million (Q1 2026), $23.0 million (Q4 2025), and $3.0 million (Q1 2025).